[ad_1]
The pharmaceutical company announced on Tuesday that Japan has agreed to purchase the Novabax COVID-19 vaccine manufactured by Takeda Pharmaceutical 150 million times.
The drug company and Japan’s largest drug company said in a statement that they are waiting for regulatory approval and are preparing to manufacture the Novavax COVID-19 vaccine domestically for distribution from early next year.
Takeda said the vaccine is still in clinical trials in Japan. Novavax has licensed and transferred manufacturing technology to enable Takeda to manufacture vaccines, the company said.
The latest agreement follows a previous agreement between the pharmaceutical company and the Japanese government to produce about 250 million Novavax vaccines for COVID-19, a disease caused by the CCP (Chinese Communist Party) virus. ..
The Novavax COVID-19 vaccine, made using protein-based technology, works by introducing into the immune system an adjuvant made from viral spike proteins made from moth cells and a natural Kiraya tree extract. To do. It does not contain live or inactivated viruses and cannot replicate or cause COVID-19.
The double-dose regime of the Novavax COVID-19 vaccine has shown nearly 90% efficacy against the original strain of COVID-19. New England Journal of Medicine..
Dr. Robert Malone, a pioneer of mRNA vaccines, spoke to Epoch TV’s “American Thought Leaders” in July, saying that Novavax’s COVID-19 vaccine is a more traditional vaccine, “the’gene vaccine strategy’provided by the mRNA vaccine.”
Talk to Nebraska medicine, Dr. Diana Florescu, MD, said Novavax is also suitable for people who are allergic to polyethylene glycol (PEG), an adjuvant used in Pfizer and Moderna vaccines that boost the recipient’s immune response.
The Pfizer and Moderna vaccines are mRNA vaccines, and the AstraZeneca vaccine and Johnson & Johnson vaccines are viral vector vaccines.
Takeda is also responsible for the import and distribution of approximately 50 million doses of Moderna vaccine this year and another 50 million doses next year.
Last month, more than 2.6 million Moderna COVID-19 doses were stopped by Japanese health regulators following the discovery of pollution problems.
The Ministry of Health said on Monday that a third party had died after being shot by recalled Moderna supplies. The first two deaths reported in the country in connection with the administration of contaminated Moderna were two men aged 30 and 38.
Investigation revealed stainless steel contaminants in some vials. In a joint statement, Moderna and Takeda said the pollution dates back to production carried out by Spanish contractor ROVI Pharma Industrial Services. The survey was conducted by both companies.
“Stainless steel is routinely used for heart valves, joint replacement, metal sutures and staples, so injecting the particles identified in these lots in Japan also increases medical risk. Is not expected, “says Takeda. Modana said In a statement last week.
Takeda said Tuesday that the causes of death are under investigation and there is no evidence that they are vaccine-related.
As of September 7, about 58% of the population has been vaccinated with COVID-19 vaccine at least once. Since the beginning of the pandemic, there have been approximately 16,400 COVID-19-related deaths in the country.
Reuters contributed to this report.
Isabelle van Brugen
Reporter
Isabel van Brugen is an award-winning journalist and currently a news reporter for The Epoch Times. She holds a master’s degree in newspaper journalism from City, University of London.
[ad_2]